|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
ARD6123 AVE0005B/2001, NCT00284141
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
ARD6122 AVE0005, NCT00327171
|
|
|
|
|
|
|
|
Last Modified: 3/14/2008  First Published: 8/18/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
NCCTG-N0537 N0537, NCT00369655
|
|
|
|
|
|
|
|
Last Modified: 9/17/2008  First Published: 11/22/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
CCC-PHII-76 7533, NCT00407485
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
ARD6772 AVE0005, NCT00396591
|
|
|
|
|
|
|
|
Last Modified: 6/3/2008  First Published: 4/13/2007 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Temporarily closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
GOG-0229F GOG-0229F, NCT00462826
|
|
|
|
|
|
|
|
Last Modified: 4/21/2005  First Published: 5/1/2002 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
25 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
MSKCC-01131 REGENERON-VGFT-ST-0103, NCI-G02-2065, NCT00036946
|
|
|
|
|
|
|
|
Last Modified: 4/7/2005  First Published: 9/1/2002 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
25 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
MSKCC-02020 REGENERON-VGF-ST-0105, NCI-G-02-2101, NCT00045266
|
|
|
|
|
|
|
|
Last Modified: 11/1/2007  First Published: 4/23/2004 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
MSKCC-03138 REGENERON-VGFT-ST-0304, NCT00082823
|
|
|
|
|
|
|
|
Last Modified: 10/30/2007  First Published: 4/23/2004 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
MSKCC-03137 REGENERON-VGFT-ST-0202, NCT00083213
|
|
|
|